Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ZX008 for rare seizure disorders
NL-OMON54815Phase 3Active, not recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fenfluramine in Dravet syndrome, Lennox-Gastaut syndrome (LGS), epileptic encephalopathy, seizure disorder, sponsored by Zogenix, Inc.. Started Sep 2020; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)epileptic encephalopathyseizure disorder
Beyond the preview
Go deeper on NL-OMON54815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54815.